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Letter by Kunz et al Regarding Article, 
“Systematic Review of the Cost and Cost-
Effectiveness of Rapid Endovascular Therapy 
for Acute Ischemic Stroke”
To the Editor:
We read with great interest the article by Sevick et al1 that 
systematically reviewed and synthesized the literature on cost-
effectiveness of endovascular therapy combined with standard 
care (EVT+SC) in acute ischemic large-vessel occlusion stroke. 
The authors conclude that EVT+SC is a cost-effective interven-
tion when adopting willingness-to-pay thresholds of $50 000 per 
quality-adjusted life year compared with SC alone. Sevick et al 
also demonstrate the applicability of this conclusion across sev-
eral different healthcare systems in Europe and North America.
We would like to highlight and add an important recent aspect 
about the source of cost data in the United States to this review. 
In the recently published cost-effectiveness analysis by Shireman 
et al,2 the decision analytic model made use of contemporary cost 
data based on the actual acute costs within the first 90 days on the 
patient level within the SWIFT-PRIME trial (solitaire with the 
intention for thrombectomy as primary endovascular treatment 
for acute ischemic stroke). Moreover, contemporary long-term 
cost data were retrieved from a large cohort of 2 stroke centers in 
the United States within the time period of 2010 to 2014. These 
contemporary cost data are significantly higher (≈2) than the pre-
vious cost data applied in the United States cost-effectiveness 
analyses on EVT, which were based on estimates from an eco-
nomic model established in 1996 and consequently inflated to 
2015 US dollars.3,4
Applying patient outcome data from the SWIFT-PRIME trial 
resulted in overall cost-savings for the strategy EVT+SC (lifetime 
costs for EVT+SC, $215 781; lifetime costs for SC, $238 984; 
incremental quality-adjusted life years, 1.74).2 In fact, applying 
these contemporary cost data to our own analytic model4 equally 
resulted in long-term cost-savings when patients are treated 
with EVT+SC (lifetime costs for EVT+SC, $217 044; lifetime 
costs for SC, $252 190; incremental quality-adjusted life years, 
1.59; thus, EVT+SC is the dominant, ie, cost-saving strategy). 
Therefore, EVT+SC was not only cost-effective but also led to 
lifetime cost-savings in the United States setting.
A cost-utility analysis performed in the United Kingdom 
by Lobotesis et al5 also implied lifetime cost-savings in patients 
treated with EVT+SC, which might also be explained by the fact 
that significantly higher acute and long-term treatment costs were 
applied than in the previous United States studies. These cost data 
were also based on more updated cost estimations derived from 
stroke registries in the United Kingdom. Accordingly, multiple 
studies have shown the large impact of in particular long-term 
cost data on the cost-effectiveness of EVT as demonstrated by 
sensitivity analyses.2–5
Taken together, we would like to convey the message that per-
forming EVT in patients with acute ischemic large-vessel occlu-
sion stroke is not only cost-effective in the United States setting 
but likely also cost-saving during the patient life time compared 
with only treating patients with SC. Adopting a healthcare payer 
perspective, this aspect may, therefore, have fundamental impli-
cations on the nationwide implementation of EVT.
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